Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

"New technologies are required to fill the gap and reverse resistance to existing antibiotics"

BioSpectrum Asia

|

July 2023

Established in 2021, Lixa is an Australian biotechnology company developing revolutionary, broadly applicable and scalable solutions for Antimicrobial Resistance (AMR). The firm is developing NeoX, a disruptive, proprietary, antibiofilm platform technology to resolve recalcitrant, resistant and recurring bacterial infections across human, animal and environmental health. Dr Maud Eijkenboom, CEO, Lixa highlights the state of AMR fight in Asia and why investing in newer technologies such as biofilms is crucial to defeat AMR. Edited excerpts;

- Ayesha Siddiqui

"New technologies are required to fill the gap and reverse resistance to existing antibiotics"

Established in 2021, Lixa is an Australian biotechnology company developing revolutionary, broadly applicable and scalable solutions for Antimicrobial Resistance (AMR). The firm is developing NeoX, a disruptive, proprietary, antibiofilm platform technology to resolve recalcitrant, resistant and recurring bacterial infections across human, animal and environmental health. Dr Maud Eijkenboom, CEO, Lixa highlights the state of AMR fight in Asia and why investing in newer technologies such as biofilms is crucial to defeat AMR. Edited excerpts;

What is being done to tackle AMR within APAC?

In 2015, the Sixty-seventh World Health Assembly endorsed The Global Action Plan for containment of AMR, which called for participating countries to develop their own AMR National Action Plan (NAP). To date, between 73 and 100 per cent of APAC countries have created, and made available, their NAP. There is still a lot of work that needs to be done. An overprescription of antibiotics in humans fuels the AMR cycle and creates more superbugs. Therefore there is a need to raise more awareness of AMR within the communities. The elephant in the room is the use of antibiotics in livestock, which can cover 70 per cent of all antibiotics usage in the world. We need nonantibiotic approaches to alleviate this situation.

In your opinion, which APAC countries have shown significant progress in addressing AMR? What specific measures or interventions have contributed to their success?

Let’s look at a few countries and their attempts to combat AMR.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Translate

Share

-
+

Change font size